Healthcare as a Service strategy and the vision of next-generation pharmaceutical companies.
Our company will hold a business seminar. 【Practical Insights Gained from the Seminar】 - Designing care pathways to incorporate HaaS into business strategy - Diagnosis, treatment, and monitoring collaboration through T2TM - Redesigning the pharmaceutical business with an eye on 2030-2040 【Target Industries and Departments】 - Management planning, business strategy, and new business departments of pharmaceutical companies - Business development departments of diagnostic drug, medical device, and digital health companies - DX, data utilization, and alliance personnel in the healthcare sector - Research and development and portfolio strategy departments 【Seminar Details】 ■ Date and Time: November 19, 2026 (Thursday) 16:30 - 18:30 (Doors open at 16:00) ■ Venue: JPI Conference Square ■ Address: 5-2-32 Minamiazabu, Minato-ku, Tokyo, Kowa Hiroo Building ■ Participation Method: In-person, live streaming, archived streaming ■ Speaker: Mr. Gaku Sakaguchi, Head of Diagnostic Drug Business Division, Shionogi & Co., Ltd. *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Lecture Overview】 Due to aging populations, constraints on medical resources, and advancements in precision medicine and AI/digital technologies, the competitive axis of the pharmaceutical industry is shifting from the superiority of individual products to the entire care pathway that achieves patient outcomes. Even excellent pharmaceuticals cannot fully realize their value unless the processes of identifying appropriate patients, diagnosis, treatment initiation, and monitoring function continuously. In this lecture, with the key message of "from product competition to patient outcome competition," we will introduce the Healthcare as a Service (HaaS) strategy promoted by Shionogi & Co., Ltd. and the concept of Test to Treat and Monitor (T2TM), and discuss the next-generation growth strategy that integrates drug discovery with diagnostics, digital technology, and data. 【Lecture Topics】 ■Transition from product competition to patient outcome competition ■Healthcare as a Service (HaaS) strategy ■Implementation of Test to Treat and Monitor (T2TM) ■The image of next-generation pharmaceutical companies ■Related Q&A ■Business card exchange and networking (limited to in-person attendees)
Price information
【Participation Fee】 1 person: 37,290 yen (tax included) From 2 people onwards: 32,290 yen (Tax included / If multiple applications are made from the same organization, please register simultaneously. Additional registrations after applying for 1 person will not be eligible for the discount.) Special offer: For those affiliated with local public organizations, the fee is 11,000 yen per person (tax included / applicable only for on-site attendance or live streaming).
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
JPI Corporation (Japan Planning Institute) has been providing valuable information for executives and senior management involved in the execution of national policies and national projects, supporting the dissemination of state policies as a 'bridge of knowledge' between 'government', 'administration', and 'citizens' in the form of exclusive real seminars for participants for half a century, aiming to create national knowledge.
